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Treatment of alopecia areata is dependent on age of
patient as well as the extent and duration of scalp
involvement. Treatments include steroids, topical
immunotherapy, topical minoxidil, anthralin, and
immunosuppressants. Each case must be dealt with
on a customized individual basis.
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There are no FDA (Food and Drug Administration)-approved
treatments for alopecia areata (AA). Many therapeutic options
exist, but none are curative or preventive (Shapiro, 2011). For
many reasons, it is difficult to assess treatment options for AA.
There is a high rate of spontaneous remission in patchy AA
(Alkhalifah, et al., 2010). There is also paucity of randomized-
controlled trials investigating treatment efficacy. Another impor-
tant drawback is the great variation in treatment outcome
evaluation (Alkhalifah, et al., 2010). To overcome this issue in
particular, the Severity of Alopecia Tool score seems to be ideal.
LOCALIZED THERAPIES
Intralesional corticosteroids
For adult patients with limited involvement, intralesional
corticosteroids (preferably triamicinolone acetonide) are con-
sidered first-line therapy. Triamicinolone acetonide is injected
in the deep dermal/upper subcutaneous plane using a ½ inch
long 30-gauge needle: 0.1 ml is injected at 0.5–1-cm intervals
every 4–6 weeks. Various concentrations (2.5–10 mg ml1) are
used, but 5 and 2.5 mg ml 1 are the preferred concentrations
used by the author for the scalp and face, respectively. The
maximum dose per session was suggested to be 20 mg of
triamcinolone acetonide. Topical anesthetic cream can be
applied before treatment to minimize pain, especially when
treating younger patients. Treatment should be stopped if there
is no improvement after 6 months. Side effects include transient
atrophy and telangiectasia, which can be prevented by the use
of smaller concentrations and volumes, minimizing the number
of injections per site, and avoiding injecting too superficially.
Topical corticosteroids
Midpotent and potent topical corticosteroids are widely used
in the treatment of AA. The evidence for their efficacy is
limited. Tosti et al. (2003) showed that 28.5% of patients had
almost complete hair regrowth and 17.8% of patient had
long-term benefit on the treated side. In another randomized,
double-blind, placebo-controlled trial, 47 of 0.05% clobetasol
propionate foam-treated patients had 425% hair regrowth,
and 25% of participants had hair regrowth 450%. No
significant modifications in cortisol and adrenocorticotropic
hormone blood levels were observed during this trial. On the
other hand, another randomized, double-blinded, placebo-
controlled trial using desoximetasone cream 0.25% showed
that the complete regrowth rates in the active and control
groups were 57.6 and 39.2%, respectively. These results were
not statistically significant when compared with placebo.
Side effects include folliculitis (more with ointment com-
pared with foam formulations), rarely skin atrophy and
telangiectasia. The relapse rate varies from 37 to 63% after
topical corticosteroid treatment has stopped and even with
continuation of therapy.
Minoxidil
In a double-blind, placebo-controlled trial on extensive AA,
3% minoxidil under occlusion with petrolatum resulted in hair
regrowth in 63.6% compared with 35.7% in the placebo arm.
Only 27.3% of minoxidil patients had cosmetically acceptable
hair growth. A dose–response efficacy was shown in a study
comparing 1 and 5% topical minoxidil in the treatment of
patients with extensive AA. The response rates were 38 and
81% with 1 and 5% topical minoxidil, respectively. Minoxidil
5% solution twice daily is used as adjuvant treatment to
conventional AA therapy (with mainly topical or intralesional
corticosteroids). Contact dermatitis and hypertrichosis are
the most common side effects. Contact dermatitis can be
minimized by using minoxidil foam which does not contain
propylene glycol.
Anthralin
There are a few uncontrolled case series assessing anthralin
efficacy in the treatment of AA. Response rates of 75% in
patchy AA patients and 25% in alopecia totalis patients have
been reported. Anthralin cream 0.5–1.0% was used to treat 68
patients with severe AA. Cosmetic response was seen in 25%
of the patients.
Anthralin 1% cream can be used as short contact therapy.
It is applied daily for 15–20 min initially and then washed.
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The contact time is increased by 5 min weekly up to 1 h or
until low-grade dermatitis develops. The contact time is then
fixed and continued daily for at least 3 months before judging
the response to treatment. Anthralin should produce a mild
irritant reaction in order to be effective. Side effects include
severe irritation, folliculitis, regional lymphadenopathy, and
staining of skin, clothes and fair hair. Patients should avoid eye
contact with this chemical, and the treated area should be
protected from the sun.
Topical immunotherapy
The mechanism of action of topical sensitizers is poorly
understood. Many theories have been suggested, including
antigenic competition, perifollicular lymphocytes apoptosis,
changes in the peribular CD4/CD8 lymphocyte ratio, and
interleukin-10 secretion after diphenylcyclopropenone (DPCP)
application.
Dinitrochlorobenzene was the first topical sensitizer to
be used in the treatment of extensive AA since 1976, but it
has been discontinued because it has been shown to be
mutagenic in the Ames test. Squaric acid dibutylester (SADBE)
and DPCP are the two compounds still in use today. DPCP
is preferred, because it is cheaper and is more stable in
acetone. Although no randomizedcontrolled trials have eval-
uated the effectiveness of topical immunotherapy in AA,
observational studies have used the half-head method to
control for spontaneous regrowth of hair. A comprehensive
review of published topical immunotherapy studies
(SADBE¼ 13 trials; DPCP¼17 trials) found little difference
between the two agents. The success rate of DPCP and SADBE
is about 50–60% with a wide range of 9–87%. The largest
reported series of DPCP treatment found that cosmetically
acceptable regrowth was achieved in 17.4% of patients with
alopecia totalis/universalis, 60.3% with 75–99% AA, 88.1%
with 50–74% AA, and 100% with 25–49% AA. A lag of
3 months was present between initiation of therapy and
development of significant hair regrowth in the first respon-
ders. Relapse after achieving significant regrowth developed
in 62.6% of patients with median time to relapse being 2½
years. Although contact immunotherapy has been used mainly
for adults, there are reports of success in the pediatric
population.
A vesicular or bullous reaction is one of the undesired
adverse effects of topical sensitizers. If this reaction develops,
the patient should wash off the contact sensitizer and a topical
corticosteroid should be applied to the affected area. Other
adverse effects include cervical and occipital lymphadeno-
pathy, facial and scalp edema, contact urticaria, flu-like
symptoms, erythema multiforme-like reactions, and pigmen-
tary disturbances (hyperpigmentation, hypopigmentation, dys-
chromia in confetti, and even vitiligo).
Phototherapy
Randomized controlled trials for phototherapy with oral or
topical psoralen plus ultraviolet A light (PUVA) are lacking.
Two large retrospective studies showed that the response rate
is no better than the spontaneous remission rate. Insufficient
evidence as well as the risk of cutaneous malignancies with
PUVA make it less a favored treatment option. Narrow-band
ultraviolet B was not effective in a retrospective analysis of 25
AA patients. A few case series have shown successful results
with 308-nm excimer laser in treating patchy AA. The initial
fluences were 50 mJ cm 2 less than the minimal erythema
dose. Fluences were then increased by 50 mJ cm2 every two
sessions. Each patch was treated twice a week for a maximum




Systemic corticosteroids have been used for decades in
patients with extensive AA. Several regimens have been used
with varying success. The only randomized placebo-con-
trolled study on oral prednisolone was published in 2005.
Forty-three patients with extensive AA were randomized to
receive prednisolone 200 mg weekly or placebo. The treat-
ment period was 3 months followed by 3 months observation
time. Significant hair regrowth was noted in 35% of patients in
the treatment group compared with none in the placebo
group. The relapse rate was 25% during the observation
period. Significant hair regrowth was noted in 28/34 patients
(82%) with extensive AA treated with prednisolone 300 mg
once monthly for 3–6 months. Poor response was associated
with the presence of other autoimmune abnormality, nail
involvement, and universalis form. Only 15% of the patients
had side effects in that report.
The side effects of systemic steroids include hyperglycemia,
osteoporosis, cataracts, immunosuppression, mood changes,
obesity, dysmenorrhea, acne, and cushing syndrome. The
reported relapse rate is 14–100%. The addition of 2% topical
minoxidil three times daily may alleviate post-steroid relapse.
Systemic steroids used in AA is less favored option because of
the side effect profile and high relapse rate.
Cyclosporine
Cyclosporine is an immunosuppressant agent that inhibits
helper T-cell activation and suppresses interferon gamma
production. Cyclosporine alone or in conjunction with sys-
temic steroids was tried with variable results. The success rate
ranges from 25 to 76.7%. Notably, however, AA has been
reported in several organ transplant patients who were taking
Cyclosporine. One report suggested that increased serum
soluble interleukin-2 receptor level and lower interleukin-18
level at baseline were associated with a poor response to a
combination of cyclosporine and methylprednisolone.
Cyclosporine is not a preferred option in AA because of
high side-effect profile and relapse rate. Side effects include
nephrotoxicity, immune suppression, hypertension, and
hypertrichosis of body hair. Further studies in humans are
needed to assess the efficacy and safety of this specific
formulation.
Methotrexate
Methotrexate (15–25 mg week1) alone or in conjunction
with 10–20 mg day1 of prednisone resulted in complete
regrowth in 57 and 63% of patients, respectively. The onset
J Shapiro
Current Treatment of Alopecia Areata
www.jidonline.org S43
of hair regrowth was noted after a median delay of 3 months.
Relapsed rate was 80% (16 out of 20 responders). Seven
patients (21%) experienced adverse events consisting of
transient elevated transaminases, persistent nausea, and lym-
phocytopenia. Using the same regimens, complete hair
regrowth was achieved in 64% of 22 alopecia totalis/AU
patients. In a retrospective study including 14 children
with severe AA treated with methotrexate (mean dose of
18.9 mg week1), response rate was 38%.
Psychosocial support
AA is associated with high psychiatric comorbidities
(mainly adjustment disorder, generalized anxiety disorder,
and depressive disorders). The efficacy of antidepressants in
AA treatment has not been evaluated by large-scale rando-
mized control trials. In a small trial of eight AA patients treated
with 20 mg paroxetine, a selective serotonin reuptake inhibitor
and five patients with placebo for 3 months, complete hair
regrowth was observed in two patients in the paroxetine group
versus one patient in the placebo arm. Four patients in the
paroxetine group showed partial hair regrowth. Willemsen
et al. (2006) showed 75–100% hair regrowth in 12 of 21
patients with extensive AA after 3–8 sessions of hypnotherapy.
In the follow-up period (ranging from 4 months to 4 years), the
relapse rate was 42%. The small sample size and less than
optimum hair regrowth assessment make the evaluation of
some trials of antidepressants difficult.
Support groups that involve regular meetings of AA patients
and family members can be an invaluable resource for them.
Patients can derive emotional support and information that
can help them develop positive coping strategies, overall
improved quality of life, and increased treatment compliance.
The National Alopecia Areata Foundation (NAAF; www.naaf.
org) provides patients and physicians with brochures, research
updates, bimonthly newsletters, a pen pal program, sources for
scalp prostheses, and many patient conferences. Also, the
NAAF supports research and research workshops that add to
the scientific knowledge about AA.
Management plan
At the patient’s first visit, a careful medical history and a
good physical examination should be carried out, including
an examination of all hair-bearing areas and nails. Full
information about his or her disease, including the relapsing
nature of AA, prognosis, and risk/benefit ratio of treatment
options, should be provided. No routine testing is required
for AA patients. Because of the possibility of spontaneous
remission in 34–50% of patients within 1 year, some
patchy AA patients can be just followed up without active
intervention. If the patient opted for active treatment, options
would be offered according to the patient’s age and extent of
the disease.
For children aged o10 years, a combination of 5%
minoxidil solution twice daily with a midpotent topical
corticosteroid is the first line of therapy. If there is no response
after 6 months, short-contact anthralin can be tried. For
patients aged 410 years with o50% scalp involvement,
intralesional injections of triamicinolone acetonide is the
author’s first option for therapy. If there is no improvement
after 6 months, other therapeutic options can be offered,
including 5% topical minoxidil twice a day, potent Topical
corticosteroid under occlusion at night, and short-contact
anthralin.
For those with 450% scalp involvement, topical immuno-
therapy with DPCP is the treatment of choice. For those
patients who respond only partially, intralesional triamicino-
lone acetonide injections are used to treat the resistant
alopecic patches. DPCP may be discontinued if there is no
response by 6 months of treatment. Alternative remedies
include 5% minoxidil solution, Topical clobetasol propionate
nightly under occlusion, or short-contact anthralin. Systemic
agents can be offered if this fails. Minoxidil 5% solution with
or without intralesional injections of triamicinolone acetonide
2.5 mg cc1 (maximum, 1 cc) can be administered to AA of
the eyebrows.
Dermatography or medical tattooing of the eyebrows may
be suggested to AA patients with prolonged eyebrow loss.
Scalp prostheses, such as wigs, hairpieces, or other scalp
coverings may be valuable options for AA patients during
treatment or when treatment fails.
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